These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8773159)

  • 1. Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials.
    Ebling WF; Levy G
    Ann Pharmacother; 1996 Jan; 30(1):12-9. PubMed ID: 8773159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations.
    Fullerton T; Forrest A; Levy G
    J Pharm Sci; 1996 Jun; 85(6):600-7. PubMed ID: 8773956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of effect-controlled clinical trials of drugs with pharmacodynamic hysteresis using sparse data.
    Ebling WF; Matsumoto Y; Levy G
    Pharm Res; 1996 Dec; 13(12):1804-10. PubMed ID: 8987075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficiencies of randomized concentration- and dose-controlled clinical trials.
    Endrenyi L; Zha J
    Clin Pharmacol Ther; 1994 Sep; 56(3):331-8. PubMed ID: 7924129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect.
    Millenbaugh NJ; Wientjes MG; Au JL
    Cancer Chemother Pharmacol; 2000; 45(4):265-72. PubMed ID: 10755313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?
    Dutta S; Matsumoto Y; Ebling WF
    J Pharm Sci; 1996 Feb; 85(2):232-9. PubMed ID: 8683454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacodynamic Modeling Using the Sigmoid E
    Proost JH; Eleveld DJ; Struys MMRF
    AAPS J; 2020 Dec; 23(1):10. PubMed ID: 33367961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity.
    Liu F; Walters SJ; Julious SA
    BMC Med Res Methodol; 2017 Oct; 17(1):149. PubMed ID: 28969588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
    Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficiency concept in pharmacodynamics.
    Alván G; Paintaud G; Wakelkamp M
    Clin Pharmacokinet; 1999 May; 36(5):375-89. PubMed ID: 10384860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Felodipine pharmacokinetics and plasma concentration vs effect relationships.
    Blychert E
    Blood Press Suppl; 1992; 2():1-30. PubMed ID: 1343111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between pharmacokinetic half-life and pharmacodynamic half-life in effect-time modeling.
    Keller F; Czock D; Zellner D; Giehl M
    Int J Clin Pharmacol Ther; 1998 Mar; 36(3):168-75. PubMed ID: 9562234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials?
    Grahnén A; Karlsson MO
    Clin Pharmacokinet; 2001; 40(5):317-25. PubMed ID: 11432535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized exposure-controlled trials; impact of randomization and analysis strategies.
    Karlsson KE; Grahnén A; Karlsson MO; Jonsson EN
    Br J Clin Pharmacol; 2007 Sep; 64(3):266-77. PubMed ID: 17425629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
    Plock N; Facius A; Hartmann L; Baumann S; Nave R
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):495-508. PubMed ID: 23611571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam.
    Albrecht S; Ihmsen H; Hering W; Geisslinger G; Dingemanse J; Schwilden H; Schüttler J
    Clin Pharmacol Ther; 1999 Jun; 65(6):630-9. PubMed ID: 10391668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of pharmacodynamic recession slopes for direct and indirect response models.
    Krzyzanski W; Jusko WJ
    J Pharmacokinet Biopharm; 1998 Aug; 26(4):409-36. PubMed ID: 10214560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and analysis of in vitro antitumor pharmacodynamic studies.
    Kalns JE; Millenbaugh NJ; Wientjes MG; Au JL
    Cancer Res; 1995 Nov; 55(22):5315-22. PubMed ID: 7585594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.